ARS Pharmaceuticals, Inc. (SPRY)
| Market Cap | 933.13M -22.0% |
| Revenue (ttm) | 142.77M +5,459.7% |
| Net Income | -80.04M |
| EPS | -0.82 |
| Shares Out | 98.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 762,128 |
| Open | 9.27 |
| Previous Close | 9.45 |
| Day's Range | 9.26 - 9.64 |
| 52-Week Range | 6.66 - 18.90 |
| Beta | 0.74 |
| Analysts | Strong Buy |
| Price Target | 35.00 (+270.76%) |
| Earnings Date | Mar 19, 2026 |
About SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SPRY stock is "Strong Buy." The 12-month stock price target is $35.0, which is an increase of 270.76% from the latest price.
News
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock
SPRY's main product is Neffy, which is a needle-free epinephrine spray. Its sales are ramping quickly, and Q3 2025 sales hit $31.3 million. My core thesis is that Neffy's more convenient delivery mech...
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
-Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epin...
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market EURneffy in th...
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharm...
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ: AQST).
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a ...
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect thems...
ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. ( SPRY) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President, CEO & Dire...
ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating
ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics an...
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may alrea...
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine nasal spray) Oral presentation to report results from real...
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie...
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine nasal spray)
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to bet...
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical co...
ARS Pharmaceuticals: A Significant Upside Is Expected From neffy
ARS Pharmaceuticals offers significant upside driven by neffy, the only FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. ARS faces near-term pressure from a patent chall...
ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair
– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NE...
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated w...
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect thems...
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer K...
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
$15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie...
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
EUR neffy ( neffy ® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children ( > 30 kg) living with severe allergic reactions
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas ...